不同剂量阿托伐他汀钙对稳定型心绞痛患者S100 A12、hs-CRP的影响

摘要

Objective To investigate the effects of different doses of atorvastatin therapy on the levels of S100A12 and hypersensitive C-reactive protein (hs-CRP) in patients with stable angina pectoris (SAP). Methods Ninty cases were included in normal control group ( control group);180 cases of SAP patients were randomized into atorvastatin 10 mg group (10 mg group,n=90) and atorvastatin 20 mg group (20 mg group,n=90). Based on stand-ard treatment,patients in 10 mg group and 20 mg group were given atorvastatin 10 mg/d and 20 mg/d taken orally. The levels of S100A12 and hs-CRP of the three groups were measured before and 6 and 12 weeks after treatment. Results The concentration of serum S100A12 and hs-CRP in 10 mg group and 20 mg group was significantly higher than that of control group (P<0. 001). At 6 and 12 weeks after treatment,the serum levels of S100A12 and hs-CRP in 10 mg group and 20 mg group were significantly lower than before treatment,and it was much lower at 12 weeks after treat-ment (P<0. 001);At 6 weeks after treatment,the level of serum S100A12 and hs-CRP in 20 mg group decreased more significantly than that of 10 mg group (P =0. 002,P =0. 042). After treatment of 12 weeks,the levels of serum S100A12 and hs-CRP in 20 mg group decreased more significantly than those of 10 mg group (P<0. 001). The de-cline values of S100A12 and hs-CRP serum before and after treatment in 20 mg group were more significant than those of 10 mg group (P <0. 001). Linear correlation analysis showed that S100A12 level was related to hs-CRP (r =0. 663,P<0. 001). The differences of S100A12 levels before and after treatment were positively correlated with those of hs-CRP levels before and after treatment in 10 mg group and 20 mg group(r=0. 275,P=0. 009). Conclusion Atorvastatin can reduce the concentration of S100A12 and hs-CRP in SAP with anti-inflammation effects.%目的 研究稳定型心绞痛患者经过不同剂量阿托伐他汀治疗后炎症因子S100A12、hs-CRP的变化.方法 正常对照组(对照组)90例;稳定型心绞痛患者180例,随机分为阿托伐他汀10 mg治疗组(10 mg组,90例)和阿托伐他汀20 mg治疗组(20 mg组,90例).在标准化治疗基础上,10 mg组和20 mg组患者分别给予阿托伐他汀10、20 mg/d,检测治疗前及治疗后6、12周三组患者的S100A12、hs-CRP水平.结果 10 mg组及20 mg组S100A12、hs-CRP水平均显著高于对照组(P<0.001).10 mg组、20 mg组患者治疗6、12周后,S100A12、hs-CRP均较治疗前显著下降;治疗12周较治疗后6周进一步下降,差异均有统计学意义(P<0.001).治疗后6周,20 mg组S100A12、hs-CRP水平较10 mg组下降更明显(P=0.002,P=0.042).治疗后12周,20 mg组S100A12、hs-CRP水平较10 mg组下降更明显(P<0.001).治疗后,20 mg组S100A12、hs-CRP血清水平降幅较10 mg组更显著,差异有统计学意义(P<0.001).S100A12、hs-CRP水平存在相关性(r=0.663,P<0.001).10 mg组、20 mg组治疗前后S100A12、hs-CRP水平差值呈正相关关系(r=0.275,P=0.009).结论 阿托伐他汀可使稳定型心绞痛患者S100A12、hs-CRP血清水平下降,具有抗炎作用.